Tags

Type your tag names separated by a space and hit enter

Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders.
Cell Mol Life Sci. 2019 Aug; 76(16):3167-3191.CM

Abstract

As life expectancy increases worldwide, age-related neurodegenerative diseases will increase in parallel. The lack of effective treatment strategies may soon lead to an unprecedented health, social and economic crisis. Any attempt to halt the progression of these diseases requires a thorough knowledge of the pathophysiological mechanisms involved to facilitate the identification of new targets and the application of innovative therapeutic strategies. The metzincin superfamily of metalloproteinases includes matrix metalloproteinases (MMP), a disintegrin and metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS). These multigenic and multifunctional proteinase families regulate the functions of an increasing number of signalling and scaffolding molecules involved in neuroinflammation, blood-brain barrier disruption, protein misfolding, synaptic dysfunction or neuronal death. Metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are therefore, at the crossroads of molecular and cellular mechanisms that support neurodegenerative processes, and emerge as potential new therapeutic targets. We provide an overview of current knowledge on the role and regulation of metalloproteinases and TIMPs in four major neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease.

Authors+Show Affiliations

Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France. santiago.rivera@univ-amu.fr.Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31197405

Citation

Rivera, Santiago, et al. "Metalloproteinases and Their Tissue Inhibitors in Alzheimer's Disease and Other Neurodegenerative Disorders." Cellular and Molecular Life Sciences : CMLS, vol. 76, no. 16, 2019, pp. 3167-3191.
Rivera S, García-González L, Khrestchatisky M, et al. Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders. Cell Mol Life Sci. 2019;76(16):3167-3191.
Rivera, S., García-González, L., Khrestchatisky, M., & Baranger, K. (2019). Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders. Cellular and Molecular Life Sciences : CMLS, 76(16), 3167-3191. https://doi.org/10.1007/s00018-019-03178-2
Rivera S, et al. Metalloproteinases and Their Tissue Inhibitors in Alzheimer's Disease and Other Neurodegenerative Disorders. Cell Mol Life Sci. 2019;76(16):3167-3191. PubMed PMID: 31197405.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders. AU - Rivera,Santiago, AU - García-González,Laura, AU - Khrestchatisky,Michel, AU - Baranger,Kévin, Y1 - 2019/06/13/ PY - 2019/05/22/received PY - 2019/05/29/accepted PY - 2019/05/22/revised PY - 2019/6/15/pubmed PY - 2019/7/30/medline PY - 2019/6/15/entrez KW - ADAM KW - Amyotrophic lateral sclerosis KW - Huntington’s disease KW - Neurodegenerative brain disease KW - Parkinson’s disease KW - TIMP SP - 3167 EP - 3191 JF - Cellular and molecular life sciences : CMLS JO - Cell. Mol. Life Sci. VL - 76 IS - 16 N2 - As life expectancy increases worldwide, age-related neurodegenerative diseases will increase in parallel. The lack of effective treatment strategies may soon lead to an unprecedented health, social and economic crisis. Any attempt to halt the progression of these diseases requires a thorough knowledge of the pathophysiological mechanisms involved to facilitate the identification of new targets and the application of innovative therapeutic strategies. The metzincin superfamily of metalloproteinases includes matrix metalloproteinases (MMP), a disintegrin and metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS). These multigenic and multifunctional proteinase families regulate the functions of an increasing number of signalling and scaffolding molecules involved in neuroinflammation, blood-brain barrier disruption, protein misfolding, synaptic dysfunction or neuronal death. Metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are therefore, at the crossroads of molecular and cellular mechanisms that support neurodegenerative processes, and emerge as potential new therapeutic targets. We provide an overview of current knowledge on the role and regulation of metalloproteinases and TIMPs in four major neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease. SN - 1420-9071 UR - https://www.unboundmedicine.com/medline/citation/31197405/Metalloproteinases_and_their_tissue_inhibitors_in_Alzheimer's_disease_and_other_neurodegenerative_disorders_ L2 - https://dx.doi.org/10.1007/s00018-019-03178-2 DB - PRIME DP - Unbound Medicine ER -